Treatment for Uncomplicated Gonorrhea
For uncomplicated gonorrhea, administer ceftriaxone 500 mg intramuscularly as a single dose, and if chlamydial coinfection has not been excluded, add doxycycline 100 mg orally twice daily for 7 days 1.
Current Standard of Care
The 2020 CDC guidelines represent a significant shift from previous dual-therapy recommendations. The move to ceftriaxone monotherapy (with conditional doxycycline for chlamydia coverage) reflects:
- Antimicrobial stewardship concerns: The rapid rise in azithromycin resistance (nearly 5% of isolates with elevated MICs by 2018) made the previous dual-therapy approach problematic 2
- Stable ceftriaxone susceptibility: U.S. surveillance data show <0.1% of isolates with concerning MICs (>0.25 mcg/mL), indicating ceftriaxone remains highly effective 2
- Increased dosing: The dose was doubled from 250 mg to 500 mg to provide greater margin of safety against potential resistance 1
This regimen treats uncomplicated urogenital, anorectal, and pharyngeal gonorrhea at all anatomic sites 1.
Weight-Based Dosing Consideration
For patients weighing ≥150 kg (330 lbs), consider ceftriaxone 1 g IM as a single dose to ensure adequate pharmacokinetic exposure 3.
Chlamydia Cotreatment
Always add doxycycline 100 mg orally twice daily for 7 days unless chlamydial infection has been definitively excluded 2, 1. This is critical because:
- Chlamydia coinfection is common
- Doxycycline is now preferred over azithromycin for chlamydia treatment
- This avoids unnecessary azithromycin exposure that could drive further resistance
Test of Cure Requirements
Perform test of cure for all pharyngeal gonorrhea cases 3. Pharyngeal infections are harder to eradicate and more likely to harbor resistant strains.
Alternative Therapies and Cephalosporin Allergies
Critical caveat: There are essentially no recommended alternative therapies for patients with true cephalosporin allergies, particularly for pharyngeal infections 2. This represents a major treatment gap. In such cases:
- Consultation with infectious disease specialists is essential
- Consider desensitization protocols if feasible
- Spectinomycin (if available) may be used for urogenital/anorectal infections but is ineffective for pharyngeal gonorrhea
Emerging Options
Zoliflodacin, a novel oral spiropyrimidinetrione, showed non-inferiority to ceftriaxone plus azithromycin in phase 3 trials (90.9% vs 96.2% cure rates) and represents the first new class of gonorrhea treatment in nearly 20 years 4, 5. However, it is not yet widely available and should be reserved for situations where standard therapy cannot be used.
Surveillance and Reporting
Report all suspected treatment failures immediately to public health authorities. Continued monitoring through surveillance systems is essential to detect emerging ceftriaxone resistance 1.